ArticleJournal of fish diseases2026
Assessing the Potential of a Formalin-Killed Cells (FKC) Vaccine Against Edwardsiella anguillarum in Milkfish (Chanos chanos).
Article in Journal of fish diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Edwardsiella anguillarum causes Edwardsiellosis in fish, resulting in severe internal organ lesions and substantial economic losses in aquaculture. The limited efficacy of antibiotics in treating this disease, coupled with concerns regarding resistance and side effects, has driven interest in exploring fish vaccines. Various vaccine candidates derived from E. anguillarum, including inactivated cells and protein subunits, have shown potential. Here, we developed a vaccine against E. anguillarum in milkfish, and its efficacy was evaluated through vaccination challenge trials using milkfish as the target species. The formalin-killed vaccine (FKC) in combination with an adjuvant exhibited superior efficacy, achieving a relative percent survival (RPS) of 83.4%. Furthermore, the agglutination titers indicated a robust immune response in the FKC + Adjuvant group, suggesting a potent and sustained antibody response. Additionally, serum lysozyme activity was significantly higher in vaccinated fish than in controls. Immune-related gene expression analysis in spleen and head kidney revealed that IL-1β peaked at 14 days post-vaccination, indicating early pro-inflammatory response, while MHC-II showed progressive elevation, suggesting sustained antigen presentation and humoral immunity. Overall, this study underscores the effectiveness of the FKC + Adjuvant combination in enhancing immune response and protecting against bacterial pathogens in aquaculture, presenting a promising strategy for disease control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.